Isentress

Selected form

Raltegravir Potassium

Method of action: Antivirals For Systemic Use

Treatment option: Immunodeficiency, Infection

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Isentress

What is Isentress? (Raltegravir Potassium)

Property	Description
Active ingredient	Raltegravir Potassium
Pharmacological class	Integrase Inhibitor (INI), Antiretroviral agent
Origin	Synthetic compound (Pyrrolidinone subclass)
Route of administration	Oral
General purpose	Achieve and maintain viral suppression in HIV-1 infection
Available forms	Film-coated tablets, Chewable tablets, Granules for oral suspension

What Type of Medicine is Isentress?

Isentress is a prescription-only brand name for the antiretroviral agent containing the active ingredient Raltegravir Potassium. This medication is classified as an Integrase Inhibitor (INI), targeting the necessary viral enzyme integrase. This classification established Raltegravir as a First-in-class compound, representing a pivotal development in the treatment landscape for Human Immunodeficiency Virus (HIV-1) infection. The compound itself is synthetic, belonging to the pyrrolidinone chemical subclass, and is primarily utilized as a single-component product within a multi-drug combination therapy regimen.

Raltegravir Potassium and General Therapeutic Purpose

The fundamental purpose of Raltegravir Potassium is to serve as a critical component in Antiretroviral Therapy (ART), aiming to achieve and sustain viral suppression. Its action involves blocking the virus’s ability to insert its genetic material into the human host cell's DNA, thereby preventing further HIV replication. Its effectiveness is broadly supported by extensive international pharmacological studies and clinical reviews; for instance, the medication is clinically recognized for its role in rapidly reducing the viral load, which is a key measure of therapeutic success. This means the drug significantly limits the ability of the virus to multiply and spread throughout the body, providing robust control over the infection.

Available Forms and Pharmaceutical Preparations

The medication is supplied for oral administration in multiple distinct pharmaceutical preparations, a feature differentiating it from agents with limited dosing options. These include standard film-coated tablets, flavor-enhanced chewable tablets, and granules for oral suspension. This variety in forms is crucial for ensuring the medication can be taken by the entire target audience, including both adults and pediatric patients who may require differing approaches to swallowing and weight-based administration. The availability of the granules for oral suspension, for example, is a differentiating factor specifically designed for the lower-weight pediatric population.

Regulatory References

What side effects are possible with Isentress?

Possible Side Effects and Safety Information

The official safety profile for Raltegravir Potassium is structured to categorize potential reactions by frequency and the physiological systems affected, as documented by regulatory agencies. This framework helps establish the scope of possible safety characteristics observed in clinical use.

Documented Adverse Reaction Scope

Adverse reactions are classified by regulatory frequency tiers. Common reactions documented in official sources include effects such as headache, insomnia, nausea, diarrhea, and fatigue. Reactions are mapped across several System-Organ Classes (SOC), including Nervous System Disorders, Gastrointestinal Disorders, Musculoskeletal and Connective Tissue Disorders, and Hepatobiliary Disorders.

Serious Adverse Reactions and Safety Patterns

The regulatory label highlights certain serious adverse reactions. These include severe Hypersensitivity Reactions, such as Stevens-Johnson syndrome (SJS) and Toxic Epidermal Necrolysis (TEN), which may involve systemic organ dysfunction. Cases of Rhabdomyolysis and associated Myopathy have also been reported. A specific safety pattern is the potential for Immune Reconstitution Inflammatory Syndrome (IRIS), which may be observed during the initial phase of combination antiretroviral therapy (cART). The label also notes that Osteonecrosis has been reported with long-term cART exposure.

Population and Formulation Safety Notes

Specific safety considerations exist for certain populations and formulations. For example, the chewable tablet formulation contains phenylalanine (a component of aspartame), which is a key note for individuals with Phenylketonuria (PKU). Caution is advised for patients with severe underlying hepatic impairment. Additionally, the official labeling notes the risk of suicidal ideation and behavior in patients with a pre-existing history of psychiatric illness.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory documentation for Isentress (Raltegravir Potassium) indicates that the drug has a wide safety margin. Studies in healthy subjects who received acute single doses significantly exceeding the therapeutic range have shown no specific toxicity or specific dose-limiting clinical manifestations.

In cases of documented acute over-ingestion, the reported clinical manifestations were limited to mild and transient gastrointestinal symptoms, such as nausea and abdominal pain. No specific serious adverse events or life-threatening complications are directly attributed to acute overdose in the official prescribing information.

Required Emergency Actions

Because no specific antidote exists for Raltegravir Potassium overdose, the treatment protocol relies on general management strategies. Treatment should consist of general supportive measures combined with continuous clinical monitoring of the patient’s status and vital signs.

For any suspected over-ingestion, the official guidance requires that the patient seek immediate medical attention. This action is mandated to allow for prompt clinical evaluation and to institute appropriate supportive care and symptomatic management. Patients must also contact a certified poison control center for specific guidance on acute management protocols.

Therapeutic Uses of Isentress

The fundamental purpose of this medication is to provide supportive relief in the context of Human Immunodeficiency Virus (HIV) infection. Raltegravir is used as part of combination therapy for the infection. This use may assist with managing the severity of the infection and helps support patients in conditions associated with the virus. Raltegravir is used to manage HIV infection, which is relevant for addressing the key systemic challenges presented by the virus.

Raltegravir is relevant in clinical settings for three primary areas: managing viral activity, immune system support, and the stabilization of complex regimens. It is commonly used for managing symptoms related to systemic imbalance associated with high viral burden, and it is applied across conditions presenting with episodic or fluctuating manifestations related to a compromised immune system. This comprehensive management approach provides supportive relief that helps patients cope more steadily with symptom fluctuations and supports general well-being.

The medication is relevant for use in complex situations, including those involving treatment-experienced patients or viral strains that exhibit resistance. It is often used during phases when symptoms become more noticeable due to therapeutic challenges, and its inclusion in combination therapy assists with maintaining functional stability within the patient's overall treatment plan.

Quick Fact: Relief for Systemic Imbalance

Eligibility and Restrictions for Use

The eligibility for using Isentress (raltegravir) is defined by regulatory documents based on patient population, age, and specific conditions.

Eligibility Scope

Category	Official Regulatory Statement	Source Context
Populations for whom use is allowed	Adults and Pediatric patients (including infants ge 4 weeks of age) who meet a minimum weight threshold (e.g., at least 2 kg or 3 kg) for the specific formulation.	Approved for both treatment-naïve and treatment-experienced populations.
Populations for whom use is contraindicated	Patients with known hypersensitivity to the active substance, Raltegravir Potassium, or to any of the excipients in the formulation.	The contraindication is absolute, based on the component's potential.
Age-related eligibility rules	Older adults (ge 65 years) should use the medicine with caution due to a higher frequency of decreased organ function. Safety and effectiveness are not established in infants below four weeks of age.	Pediatric use is stratified by weight and age.
Condition-specific rules	Use requires caution in patients with severe hepatic impairment or a pre-existing history of severe depression/psychiatric illness. Patients with renal impairment require no dosage adjustment.	Chewable tablets contain phenylalanine and must be used with caution in patients with phenylketonuria (PKU).
Reproductive status	Use during pregnancy should be considered only if the potential benefit justifies the potential risk. Breastfeeding is not recommended for women with HIV-1 infection.	The once-daily regimen is not recommended during pregnancy.

Eligibility Classifications

Official regulatory documents classify non-eligibility as Contraindicated (Hypersensitivity), while other groups are categorized under Not Recommended (e.g., breastfeeding) or require Caution (e.g., severe hepatic impairment).

What should I know about interactions with other medicines?

The regulatory profile for Raltegravir (Isentress) defines specific interaction patterns requiring restrictions or timing separation, based on pharmacokinetic and pharmacodynamic outcomes documented by government health authorities.

The primary metabolic route for Raltegravir involves the UGT1A1 enzyme. Co-administration with strong UGT1A1 inducers, such as Rifampin, results in a documented reduction in Raltegravir plasma concentrations by increasing its metabolic clearance. Conversely, potent UGT1A1 inhibitors, such as Atazanavir, may increase Raltegravir exposure. Due to the potential for altered exposure, co-administration of certain inhibitors with the Isentress HD (1200 mg once daily) formulation is not recommended.

Administration of Raltegravir is susceptible to interference from polyvalent cations, which bind the drug in the gastrointestinal tract, leading to reduced absorption. Consequently, co-administration with antacids containing aluminum or magnesium is formally not recommended by regulatory agencies. For other polyvalent cation-containing products (e.g., certain iron or calcium supplements), the official label mandates a timing separation rule: Raltegravir must be administered at least two hours before or six hours after the cation-containing product.

Pharmacodynamic constraints include caution when co-administering Raltegravir with other medicinal products known to carry the documented risk of myopathy or rhabdomyolysis, as this combination may increase the overall risk factor. Raltegravir can be taken with or without food, though a high-fat meal may officially increase plasma exposure for the 400 mg tablet.

Mechanism of Action

Targeting the Viral Genetic Integration Pathway

Raltegravir acts as a selective Integrase Strand Transfer Inhibitor (INSTI), specifically targeting the essential HIV-1 Integrase enzyme. By binding to the enzyme's active site and chelating essential metal ions, Raltegravir physically prevents the strand transfer step, which is the necessary molecular process that integrates the viral DNA into the human host cell's genetic material.

Arresting the Viral Replication Cascade

The functional consequence of blocking strand transfer is the complete failure to form the provirus. Since the viral blueprint is not integrated into the host cell DNA, the cell cannot produce the viral messenger RNA and subsequent proteins required for new virions. This molecular arrest leads directly to the core physiological effect: a rapid systemic reduction in the circulating plasma viral load, restricting the virus's potential for replication and propagation.

Mechanism Constraint by Viral Mutation

The mechanism of Raltegravir is critically dependent on the precise structure of the Integrase active site. Genetic alterations in the viral integrase gene, known as resistance-associated mutations, can structurally modify this binding site. This change reduces Raltegravir's binding affinity, allowing the Integrase enzyme to functionally bypass the inhibitory mechanism and potentially leading to a return of viral replication.

Dosage and Administration Information

How to Use Isentress — Official Administration Guidelines

Raltegravir (Isentress) is administered via the oral route as a continuous component of long-term antiretroviral therapy. The medication is supplied in distinct forms, including film-coated tablets (400 mg and 600 mg), chewable tablets, and granules for oral suspension.

Standardized Dosing Regimens

The most common official dosing pattern for adults is 400 mg twice daily (BID). An alternative regimen is 1200 mg once daily (QD), which requires the use of two 600 mg film-coated tablets. The different available formulations are not interchangeable and must be used exactly as prescribed due to non-equivalent absorption characteristics.

Administration Procedures and Conditions

Isentress may be taken with or without food, establishing flexibility in the daily dosing schedule. Procedural adherence to the form is critical: film-coated tablets must be swallowed whole and should not be crushed, split, or chewed. Granules for oral suspension require specific preparation, involving mixing with water and administration within a short timeframe.

Population and Missed Dose Rules

Dosing for pediatric patients is strictly weight-based, necessitating the use of the chewable tablets or oral suspension forms for certain weight categories. For adult patients with mild to moderate renal or hepatic impairment, no dosage adjustment is required. If a dose is missed, patients should resume the regular schedule, skipping the missed dose if the next scheduled dose is imminent; two doses should never be taken simultaneously to compensate for a missed one.

Recent Clinical Evidence

Isentress: Recent Clinical Evidence

Evidence for Use in Patients Starting Therapy

The evaluation relied on large-scale, randomized controlled trials (RCTs) comparing the medicine against other established treatments in adults who had never taken antiretroviral medicine before (treatment-naïve). Researchers monitored the proportion of patients whose viral load levels were assessed as below detectable levels and the change in CD4 cell counts. Core findings were described at the 48-week mark, reporting patterns related to virologic outcomes observed over time.

Evidence for Use in Treatment-Experienced Patients

For adults who had previously failed therapy and carried drug-resistant strains, the research involved placebo-controlled trials where Isentress was added to an optimized background therapy (OBT). Studies monitored the assessment of changes in viral load and CD4 cell counts. The research structure means the observed findings are specific to the combination regimen. Evidence remains constrained by the need for an active background therapy in the research design.

Evidence in Pediatric and Other Special Populations

Research in children and adolescents primarily used open-label, non-comparative trials to establish dose selection. Studies examined pharmacokinetic parameters to assess whether drug levels were similar to adults and described patterns related to virologic status (viral suppression). Research indicated that the different oral formulations were not bioequivalent, resulting in distinct dose selection being studied for each specific form.

Long-Term Study Durability and Uncertainty

The evidence includes trials with follow-up periods extending well beyond the initial assessment, providing long-term observational data for up to five years. These studies monitored outcomes over prolonged periods. However, the findings may be derived from non-randomized, exploratory analyses. Research highlights where evidence is limited, particularly where sample sizes were modest in the youngest patient cohorts (infants), indicating that data for certain groups remain insufficient.

Frequently Asked Questions (FAQ)

Common questions about Isentress (FAQ)

Q: How quickly does Isentress start to lower the viral load?

A: Regulatory documents describe the medicine's mechanism of action as leading directly to a rapid systemic reduction in the circulating plasma viral load. This action restricts the virus's potential for replication. Clinical studies monitored the success of this reduction over time, with core findings often reported at the 48-week mark.

Q: Is it okay to take Isentress with common over-the-counter heartburn medicines like antacids?

A: Official information states that co-administration with antacids containing aluminum or magnesium is formally not recommended. This is because these ingredients can interfere with how the medicine is absorbed. For other products containing metal ions (polyvalent cations), official guidelines mandate a timing separation rule, requiring Isentress to be administered at least two hours before or six hours after the cation-containing product.

Q: Does Isentress interact with any vitamins or herbal supplements?

A: Regulatory information notes that products containing polyvalent cations, such as certain iron or calcium supplements, may interfere with absorption, requiring a time separation. Additionally, caution is noted regarding strong UGT1A1 inducers, which could affect the amount of raltegravir in the bloodstream. Information from authoritative sources advises discussing all current supplements and vitamins with a healthcare provider.

Q: Does Isentress carry a Black Box Warning from the FDA?

A: While the specific term 'Black Box Warning' may not be explicitly used, the regulatory safety profile highlights several serious adverse reactions. These include severe Hypersensitivity Reactions (such as Stevens-Johnson syndrome), Rhabdomyolysis (severe muscle breakdown), and the potential for Immune Reconstitution Inflammatory Syndrome (IRIS).

Q: What does the term rhabdomyolysis mean in relation to Isentress?

A: Rhabdomyolysis is a serious condition that involves the breakdown of damaged skeletal muscle tissue in the body. Regulatory labeling notes that cases of Rhabdomyolysis and associated Myopathy (muscle disease) have been reported in patients taking this medicine.

Q: Is there a risk of drug resistance developing while on Isentress?

A: Yes, regulatory documents explain the mechanism of viral resistance. Genetic alterations in the virus's integrase enzyme can lead to resistance-associated mutations. These changes structurally modify the drug's binding site, which may cause a failure of the medication to control the virus and potentially lead to a return of viral replication.

Q: What is the difference between Isentress and Isentress HD?

A: The names distinguish the two approved regimens. Isentress (400 mg tablet) is generally used in the twice-daily (BID) dosing regimen, while Isentress HD (600 mg tablet) is used to achieve the higher dose for the once-daily (QD) regimen. The different formulations are not interchangeable because their absorption characteristics differ.

Q: Is Isentress considered a first-line treatment for HIV?

A: The evidence for this medicine was established in large-scale, randomized controlled trials comparing it against other established treatments. These trials focused on treatment-naïve adults, meaning patients who had never taken antiretroviral medicine before.

Q: Is Isentress the same kind of drug as Truvada or Descovy?

A: No, they belong to different classes of medication. Isentress is classified as an Integrase Inhibitor (INI), which works by blocking the virus from inserting its genetic material into the host DNA. Truvada and Descovy belong to the Nucleoside/Nucleotide Reverse Transcriptase Inhibitor (NRTI) class, which works by blocking a different step in the viral replication process.

Q: Do many people experience insomnia or sleep problems when taking Isentress?

A: Insomnia (trouble sleeping) is listed as one of the Common adverse reactions documented in the official safety profile for the medicine. Other common effects include headache, nausea, diarrhea, and fatigue.

Q: Can taking Isentress affect your kidney function?

A: For adult patients with pre-existing mild to moderate renal impairment (kidney issues), official labeling notes that no dosage adjustment is required. While the drug is generally processed with flexibility, official documents do report kidney failure and kidney stones as less common side effects.

Q: Are there any liver concerns associated with Isentress?

A: Regulatory documents include Hepatobiliary Disorders (liver and bile duct issues) within the documented adverse reaction scope. Official information also advises caution for patients with pre-existing severe hepatic impairment (liver problems). Hepatitis has been reported as a less common side effect.

Q: How long does the drug stay in your system after stopping it?

A: Pharmacokinetic studies indicate that raltegravir is absorbed rapidly after oral administration. The medicine has a mean half-life of approximately 7 to 12 hours in healthy volunteers.

Q: Are there any known issues mixing Isentress with antibiotics?

A: Official warnings note that taking Isentress with certain other medicines that act as strong UGT1A1 inducers, such as the antibiotic Rifampin, can reduce the amount of raltegravir in the blood. This effect may alter the effectiveness of the HIV treatment.

Q: Isentress is approved for use in both adults and pediatric patients. This includes infants ge 4 weeks of age who meet a minimum weight threshold for the specific formulation being used.

A: Official regulatory documents confirm that Isentress is approved for use in both adults and pediatric patients. This includes infants ge 4 weeks of age who meet a minimum weight threshold for the specific formulation being used.

Q: Why do some people take Isentress once a day and others twice a day?

A: Both once-daily and twice-daily regimens are official, approved options for different patient populations, such as those who are just starting treatment or those who are already virologically suppressed. The once-daily regimen requires the use of the 600 mg film-coated tablets (Isentress HD), as the different tablet formulations are not interchangeable.

Q: Is there a known link between Isentress and depression or mood changes?

A: Official labeling lists depression as a reported adverse reaction. Regulatory documents also specifically note a risk of suicidal ideation and behavior in patients who have a pre-existing history of psychiatric illness.

Q: Is there a generic version of Isentress available?

A: The FDA has granted approval for a generic version of the Isentress HD formulation (raltegravir 600 mg). However, the commercial availability of generic versions is determined by drug patents and market exclusivity rights.

Q: Do you need to have regular blood tests while on Isentress?

A: Clinical trials monitored the success of therapy by assessing key indicators like viral load levels and CD4 cell counts. Furthermore, the regulatory label describes the need to monitor liver enzyme levels if a patient develops a severe hypersensitivity reaction or rash with systemic symptoms.

Q: Can I drive or operate machinery if I'm taking Isentress?

A: The drug's safety profile includes nervous system disorders, such as common reports of headache, dizziness, and insomnia. Because of these potential effects, it is noted that caution should be exercised before engaging in activities that require mental focus.

Q: Is it safe to drink alcohol while being treated with Isentress?

A: Official regulatory documents do not list a direct chemical interaction between Isentress and alcohol. However, because common side effects of the medicine include dizziness and fatigue, consuming alcohol may increase the likelihood of experiencing these effects.

Q: Is Isentress used for HIV prevention (PrEP)?

A: Isentress is formally indicated for the treatment of HIV-1 infection in combination with other antiretroviral agents to achieve and sustain viral suppression. It is not indicated for HIV prevention, which is also known as Pre-Exposure Prophylaxis (PrEP).

Q: What makes Isentress a part of the 'integrase inhibitor' class?

A: The medicine is classified as an Integrase Inhibitor because it specifically targets the essential HIV-1 Integrase enzyme. It works by physically preventing the strand transfer step, which is the required process for the virus to insert its genetic material into the human host cell's DNA.

Q: Do official documents mention any effects of Isentress on bone density?

A: Official safety documents report that Osteonecrosis (a condition involving the death of bone tissue due to lack of blood supply) has been noted with long-term exposure to combination antiretroviral therapy (cART).

Q: Is there a liquid or suspension form of Isentress for people who can't swallow pills?

A: Yes. Isentress is supplied in multiple forms, including chewable tablets and granules for oral suspension. This variety in forms helps accommodate patients, including pediatric patients, who may require different methods of oral administration.

Q: Can taking Isentress cause or worsen diabetes?

A: Clinical trial data published in regulatory documents includes the monitoring of serum glucose (blood sugar) levels as a laboratory parameter. This monitoring suggests that changes in blood sugar may be associated with its use.

Q: Does Isentress affect the way other drugs, like pain relievers, work?

A: Regulatory information focuses on the drug's metabolism via the UGT1A1 enzyme and the risk of reduced absorption when taken with polyvalent cations. Any other drug, including some pain relievers, that affects these specific chemical pathways could potentially interact.

Q: How long has Isentress been approved and on the market?

A: Raltegravir (Isentress) was first approved by the FDA on October 12, 2007, for the treatment of HIV-1 infection. It was classified as a First-in-class compound at the time of its introduction.

How should Isentress be stored and disposed of?

How to Store and Dispose of Isentress?

Official regulatory documents define the mandatory conditions for storing and discarding Isentress (Raltegravir Potassium) to ensure product integrity and safety.

Storage Conditions

Requirement	Official Regulatory Rule
Temperature	Store at 25 C (77 F); permitted excursions between 15 C to 30 C.
Container	Keep in the original container, tightly closed, to protect from moisture.
Child Safety	Mandatory to keep out of the sight and reach of children (all forms).

Stability and Disposal

Specific stability limits apply to the oral preparations. The granules for oral suspension, once mixed with water, must be used within 30 minutes. If the bottle of granules is opened, the contents must be used within 90 days. Disposal rules mandate that unused or expired Isentress must not be thrown into household garbage or poured down the drain/wastewater. The medication should be returned through an official medicine take-back program or disposed of as advised by a pharmacist according to local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.